MASSDEVICE ON CALL — Artificial pancreas technology for monitoring and moderating symptoms of diabetes could help save the U.S. healthcare system $937 million over 25 years, according to a new study.
The technology, which would combine an automated blood glucose monitor and insulin delivery system, could help prevent diabetic patients from experiencing complications associated with their disease, the researchers wrote.
"The modeling shows that insurers’ coverage of the cost of an artificial pancreas at a relatively early point in the life of a patient with diabetes would greatly reduce future complications of the disease and spending needed to treat such complications," the study’s authors wrote. "The results of this analysis support conducting a more comprehensive trial to assess the long-term impact of the artificial pancreas on glucose levels and the technology’s related costs."
CardioDx wins Medicare coverage for coronary artery disease test
Palo Alto, Calif.-based CardioDx won Medicare consideration for its coronary artery disease gene expression text, which has been on the market since June 2009.
Euro Parkinson’s device aims to automate treatment
Funded by the European Union, a team researchers are working on a wearable Parkinson’s treatment device that will detect the stiffness, tremors and other symptoms of the disease and automatically deliver anti-spasm medication.
Nanotech looks promising for treating heart failure
Researchers studying nanotechnology have regrown damaged heart tissues in animals, suggesting a new road for treating patients with heart disease.
Unprecedented study finds artificial heart feasible in babies in children
An unprecedented study involving 17 health centers concluded that Berlin Heart’s Excor pediatric ventricular assist device may provide a viable "bridge to transplant" for babies and children.